Patents by Inventor Hansen Wong

Hansen Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1
    Publication number: 20240317856
    Abstract: The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent and an anti-PD-1 antibody. Step dosing of the anti-DLL3 agent is also disclosed.
    Type: Application
    Filed: May 6, 2022
    Publication date: September 26, 2024
    Inventors: Nooshin Hashemi Sadraei, Aditya Shetty, Mukul Minocha, Marie-Anne Damiette Smit, Hansen Wong, Siddhartha Roychoudhury
  • MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
    Publication number: 20160213610
    Abstract: This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.
    Type: Application
    Filed: January 28, 2016
    Publication date: July 28, 2016
    Inventors: Mouhannad Jumaa, Tony Muchamuel, Naveen Bejugam, Hansen Wong, Christopher J. Kirk, Rahul Vishram Manek, Sanjeev Sharma
  • Modified release formulations for oprozomib
    Patent number: 9295708
    Abstract: This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: March 29, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Mouhannad Jumaa, Tony Muchamuel, Naveen Bejugam, Hansen Wong, Christopher J. Kirk, Rahul Vishram Manek, Sanjeev Sharma
  • Tazarotene derivatives
    Patent number: 9062037
    Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: June 23, 2015
    Assignee: Stiefel Laboratories, Inc.
    Inventors: Xue Ge, Hansen Wong, Wendy Huang Chern, Hans Hofland, Michael J. Bishop, Xin Frank Cai, Alan Colborn
  • TAZAROTENE DERIVATIVES
    Publication number: 20140357672
    Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Inventors: Xue GE, Hansen WONG, Wendy Huang CHERN, Hans HOFLAND, Michael J. BISHOP, Xin Frank CAI, Alan COLBORN
  • TAZAROTENE DERIVATIVES
    Publication number: 20140357669
    Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Inventors: Xue GE, Hansen WONG, Wendy Huang CHERN, Hans HOFLAND, Michael J. BISHOP, Xin Frank CAI, Alan COLBORN
  • Modified Release Formulations for Oprozomib
    Publication number: 20140113855
    Abstract: This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 24, 2014
    Inventors: Mouhannad Jumaa, Tony Muchamuel, Naveen Bejugam, Hansen Wong, Christopher J. Kirk, Rahul Vishram Manek, Sanjeev Sharma
  • TAZAROTENE DERIVATIVES
    Publication number: 20120115909
    Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.
    Type: Application
    Filed: July 16, 2010
    Publication date: May 10, 2012
    Inventors: Xue Ge, Hansen Wong, Wendy Huang Chern, Hans Hofland, Michael J. Bishop, Xin Frank Cai, Alan Colborn